ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

エトラビリン

Etravirine

HCID 193962
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
269055-15-4
標準SMILES
Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br
InChIKey
PYGWGZALEOIKDF-UHFFFAOYSA-N
分子式
C20H15BrN6O
平均分子量
435.3 g/mol
単同位体質量
434.04907

概要

Etravirine is an aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directly to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities. It has a role as an antiviral agent and a HIV-1 reverse transcriptase inhibitor. It is an aromatic ether, an organobromine compound, an aminopyrimidine and a dinitrile.

名称と識別子

優先名称
Etravirine
IUPAC
4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile
現地名
エトラビリン
英語名
Etravirine
分子式
C20H15BrN6O
分子量
435.28

名称と別名

Etravirine269055-15-4IntelenceTMC-125TMC125TMC 1254-((6-Amino-5-bromo-2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrileR165335R-165335EtravirinaTMC125 cpd4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE
名称をさらに表示
エトラビリンエトラビリン (JAN)4-({6-アミノ-5-ブロモ-2-[(4-シアノフェニル)アミノ]ピリミジン-4-イル}オキシ)-3,5-ジメチルベンゾニトリル4-[2-[(4-シアノフェニル)アミノ]-4-アミノ-5-ブロモピリミジン-6-イルオキシ]-3,5-ジメチルベンゾニトリル4-[4-(2,6-ジメチル-4-シアノフェノキシ)-5-ブロモ-6-アミノ-2-ピリミジニルアミノ]ベンゾニトリルインテレンス4-[6-アミノ-5-ブロモ-4-(2,6-ジメチル-4-シアノフェノキシ)-2-ピリミジニルアミノ]ベンゾニトリルN-(4-シアノフェニル)-6-(2,6-ジメチル-4-シアノフェノキシ)-5-ブロモピリミジン-2,4-ジアミン4-[6-アミノ-5-ブロモ-2-(4-シアノアニリノ)ピリミジン-4-イルオキシ]-3,5-ジメチルベンゾニトリルCS-1948R 165335EtorvulinEtravirine CRSEtravirine PowderSeebio EtravirineEtravirine(TMC-125)Etravirine (R165335
4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile0C50HW4FO1CHEBI:635894-(6-Amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrileDTXSID301814124-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrileBenzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-

物性

構造計算による物性補完中

XLogP
4.5
極性表面積
121 Ų
水素結合供与体数
2
水素結合受容体数
7
回転可能結合数
4
重原子数
28
形式電荷
0
複雑度
609

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Reverse Transcriptase Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

物理化学的性質

融点
265 °C · .265°C (dec.)
沸点
637.4 · 637.4±65.0 °C(Predicted)
比重(密度)
1.439 g/cm3 · 1.439 g/cm3
貯蔵温度
-20 °C · Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
溶解性
DMSO(わずかに)、メタノール(わずかに、加熱、超音波処理)
外見
個体
酸解離定数(Pka)
1.23 · 1.23±0.10(Predicted)
色
ホワイトからオフホワイト
InChI
InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)
InChIKey

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (90%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P264+P265, P270, P273, P280, P301+P317, P305+P351+P338, P330, P337+P317, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 10 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (90%)

毒性情報

Hepatotoxicity · 1 件

Serum aminotransferase elevations occur in a high proportion of patients on etravirine therapy, but increases above 5 times the upper limit of normal occur in only 2% to 3% of patients; this rate may be higher in patients who have hepatitis C coinfection. In most studies, the rate of liver enzyme elevations was no different in etravirine treated than among in comparator arms. In large clinical trials as well as open access studies, there were no reported instances of clinically apparent liver injury attributed to etravirine.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Etravirine

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
WGK 3

化学と産業

薬理情報

ATC Code · 3 件

J05AG04

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingPlasma protein binding is about 99.9% in vitro. In vitro, 99.6% is bound to albumin, and 97.66% - 99.02% is bound to 1-alpha glycoprotein.
PharmacodynamicsClinical trials have shown no prolongation of QT intervals on electrocardiograms after 8 days of dosing.
Mechanism of Action · 1 件

Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1). It directly binds reverse transcriptase and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma.

Biological Half-LifeHalf life of 9.05-41 hours.
Metabolism/MetabolitesMetabolized (in vitro) by the liver CYP450 enzymes: CYP3A4, CYP2C9, CYP2C19. The major metabolites formed by a methyl hydroxylation of the dimethylbenzonitrile moiety retained less than 90% of etravirine's activity.
FDA Pharmacological Classification · 6 件

0C50HW4FO1

ETRAVIRINE

Established Pharmacologic Class [EPC] - Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Non-Nucleoside Analog [EXT]

Mechanisms of Action [MoA] - Non-Nucleoside Reverse Transcriptase Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 3A Inducers

MeSH Pharmacological ClassificationInhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
Absorption, Distribution and Excretion

関連反応

121 件
反応記録を作成
HRID 41369 の反応式
HRID 41369生成物として
HRID 243534 の反応式
HRID 243534反応物として
HRID 243543 の反応式
HRID 243543生成物として
HRID 867268 の反応式
HRID 867268反応物として
HRID 867286 の反応式
HRID 867286反応物として
HRID 867304 の反応式
HRID 867304反応物として
HRID 867322 の反応式
HRID 867322反応物として
HRID 867340 の反応式
HRID 867340反応物として
前へ1 / 16 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
269055-15-4
PubChem CID
193962
DTXSID
DTXSID30181412
ChEMBL
CHEMBL308954
ChEBI
CHEBI:63589
UNII
0C50HW4FO1
EC Number
682-331-6
Nikkaji
J1.588.786I
PYGWGZALEOIKDF-UHFFFAOYSA-N
SMILES
C(#N)C1=CC(C)=C(OC2C(Br)=C(N)N=C(NC3=CC=C(C#N)C=C3)N=2)C(C)=C1

化学的性質

化学的特性White to Off-White Solid

Hazard Classifications
Aquatic Acute 1Aquatic Chronic 1
ストレージクラス
11 - Combustible Solids
· 4 件

Maximum oral absorption is achieved in 2.5-4 hours. Absorption is unaffected by the concomitant use of oral ranitidine or omeprazole, which decrease gastric acidity. Administration under fasting conditions resulted in a near 50% decrease in systemic exposure (AUC) when compared to administration after a meal.

After a 800mg dose of radio-labelled etraverine, 93.7% was found to undergo fecal elimination, with 81.2% - 86.4% eliminated unchanged. 1.2% of the dose was renally eliminated, changed. Etravirine is dialyzable (hemodialysis).

Distribution of etravirine into compartments other than plasma has not been evaluated in humans.

Renal clearance of etravirine is negligible (<1.2%), thus no dose adjustments are required in patients with renal impairment. Clearance is shown to be reduced in patients with Hepatitis B and/or co-infection, however, the safety profile of etravirine does not call for dosage adjustments.

用途と製造

UsesUse (kg; approx.) in Germany (2009): >50
応用分野 · 3 件

用途抗HIV薬

説明Etravirine is a second-generation NNRTI. It is indicated for use in combination with other antiretroviral agents for treating HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to the currently available NNRTIs and other antiretroviral agents. The NNRTIs, along with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), are important components of the combination regimens currently used to treat HIV-1 infection. The NRTIs/NtRTIs act by competing with the natural nucleotide substrates of reverse transcriptase for incorporation into viral DNA and subsequent chain termination. By contrast, the NNRTIs bind to an allosteric site of the enzyme and disrupt the DNA polymerase function by inducing conformational changes to the catalytic site. The allosteric binding nature of NNRTIs generally results in improved safety profile since there is no known human homolog for the drug-binding site of the enzyme.As with other NNRTIs, etravirine has many drug–drug interactions. It is a substrate of CYP3A4, CYP2C9, and CYP2C19, an inducer of 3A4, and an inhibitor of 2C9 and 2C19. Caution should be used with co-administration of inducers, inhibitors, or substrates of these enzymes. Etravirine can be synthesized starting from 5-bromo-2,4,6-trichloropyrimidine through three successive nucleophilic substitution reactions. Initial displacement with 4-aminobenzonitrile using Hu¨nig’s base, followed by reaction with sodium salt of 4-hydroxy-3,5- dimethylbenzonitrile, and subsequent ammonolysis reaction with ammonia in dioxane under pressure affords etravirine. .

使用Etravirine is an antiretroviral (anti-HIV) drug that is part of the non nucleoside reverse transcriptase inhibitor (NNRTIs or Non Nukes) family. It is used together with other antiretrovirals in treatment-experienced adult patients, who have failed previous therapy, and have HIV-1 strains which are resistant to other retrovirals and NNRTIs. Etravirine is used to delay the progression of HIV infection. By using etravirine, your immune system should improve (increase in CD4 + count) and you will be better protected against opportunistic infections.Etravirine does not cure AIDS or completely kill the HIV virus, but helps to prevent further damage by slowing down the production of new viruses. Treatment with etravirine does not reduce the risk of passing infection on to others. You will still be able to pass HIV by sexual contact, by blood transfer or by sharing needles. You should always use appropriate precautions to prevent passing HIV on to others.

上流・下流製品情報

上流原料

6-Desamino 6-Chloro Etravirine4-ヒドロキシ-3,5-ジメチルベンゾニトリルEtravirine Impurity 11
補足説明 · 1 件

定義ChEBI: An aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directl to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities